Conditions: Dyslipidemia
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 188
Healthy volunteers: yes

Brief summary:
This study will evaluate the definitive bioequivalence of tablets of MK0524A (1000 mg Extended Release (ER) Niacin/ 20 mg laropiprant) from two sources.

Detailed description:

Arms:
arm 1: MK0524A Source 1 (Phase III manufacturing site) arm 2: MK0524A Source 2 (commercial manufacturing site)

Interventions: intervention 1: niacin (+) laropiprant (Source 1) intervention 2: Comparator: niacin (+) laropiprant (Source 2)
Intervention descriptions: intervention 1: Single dose of MK0524A (ER Niacin/laropiprant 1000/20 mg) from Source 1 in one of two treatment periods. intervention 2: Single dose of MK0524A (ER Niacin/laropiprant 1000/20 mg) from Source 2 in one of two treatment periods.

Protocol document: